crenatoside and Influenza--Human

crenatoside has been researched along with Influenza--Human* in 1 studies

Other Studies

1 other study(ies) available for crenatoside and Influenza--Human

Article	Year
Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors. European journal of medicinal chemistry, 2016, Feb-15, Volume: 109 Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease. Topics: Antiviral Agents; Caffeic Acids; Drug Design; Enzyme Inhibitors; Glucosides; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Structure-Activity Relationship	2016

Article

Year

Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.

European journal of medicinal chemistry, 2016, Feb-15, Volume: 109

Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease.

Topics: Antiviral Agents; Caffeic Acids; Drug Design; Enzyme Inhibitors; Glucosides; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Structure-Activity Relationship

2016